IL15 and neoplasm: Given the overall favorable hematological safety profile of fludarabine 30 mg/m2 × 4 days and cyclophosphamide 600 mg/m2 × 3 days LD chemotherapy and its ability to support afami-cel anti-tumor activity across different indications, with no discernable difference in serum IL-15 levels compared to the higher cyclophosphamide dose schedule, the lower LD chemotherapy regimen was selected for the registration-directed phase 2 SPEARHEAD-1 trial (NCT04044768).